Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo

• Published in: Journal of virology Vol. 95; no. 8
• Main Authors: Gramatica, Andrea, Schwarzer, Roland, Brantley, William, Varco-Merth, Benjamin, Sperber, Hannah S, Hull, Philip A, Montano, Mauricio, Migueles, Stephen A, Rosenthal, Danielle, Hogan, Louise E, Johnson, Jeffrey R, Packard, Thomas A, Grimmett, Zachary W, Herzig, Eytan, Besnard, Emilie, Nekorchuk, Michael, Hsiao, Feng, Deeks, Steven G, Snape, Michael, Kiernan, Bernard, Roan, Nadia R, Lifson, Jeffrey D, Estes, Jacob D, Picker, Louis J, Verdin, Eric, Krogan, Nevan J, Henrich, Timothy J, Connors, Mark, Ott, Melanie, Pillai, Satish K, Okoye, Afam A, Greene, Warner C
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 25-03-2021
• Subjects: Vaccines and Antiviral Agents; HIV-1; SIV; in vivo study; HIV latency reversion; HIV cure
• ISSN: 0022-538X; 1098-5514; 1098-5514
• DOI: 10.1128/JVI.02393-20

An ability to activate latent HIV-1 expression could benefit many HIV cure strategies, but the first generation of latency reversing agents (LRAs) has proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs. Two glycogen synthase kinase-3 inhibitors (GSK-3i's), SB-216763 and tideglusib (the latter already in phase II clinical trials) that activate AKT/mTOR signaling were tested. These GSK-3i's reactivated latent HIV-1 present in blood samples from aviremic individuals on antiretroviral therapy (ART) in the absence of T cell activation, release of inflammatory cytokines, cell toxicity, or impaired effector function of cytotoxic T lymphocytes or NK cells. However, when administered
to SIV-infected rhesus macaques on suppressive ART, tideglusib exhibited poor pharmacodynamic properties and resulted in no clear evidence of significant SIV latency reversal. Whether alternative pharmacological formulations or combinations of this drug with other classes of LRAs will lead to an effective
latency-reversing strategy remains to be determined.
If combined with immune therapeutics, latency reversing agents (LRAs) have the potential to reduce the size of the reservoir sufficiently that an engineered immune response can control the virus in the absence of antiretroviral therapy. We have identified a new class of LRAs that do not induce T-cell activation and that are able to potentiate, rather than inhibit, CD8+ T and NK cell cytotoxic effector functions. This new class of LRAs corresponds to inhibitors of glycogen synthase kinase-3. In this work, we have also studied the effects of one member of this drug class, tideglusib, in SIV-infected rhesus monkeys. When tested in vivo, however, tideglusib showed unfavorable pharmacokinetic properties, which resulted in lack of SIV latency reversal. The disconnect between our ex vivo and in vivo results highlights the importance of developing next generation LRAs with pharmacological properties that allow systemic drug delivery in relevant anatomical compartments harboring latent reservoirs.